CULLINAN THERAPEUTICS, INC. Stock-Based Compensation
CULLINAN THERAPEUTICS, INC. (CGEM) reported Stock-Based Compensation of $16.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $8.45M, a 14.56% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.62M, a 18.75% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.31M, a 24.10% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.47M, a 0.39% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $36.04M, a 4.72% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $37.82M, a 24.27% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $30.44M, a 8.87% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $27.96M, a 14.70% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.06M 10-Q · filed 2026-08-06 | $23.38M derived: sum of 3 quarters · filed 2026-08-06 | $32.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.62M 10-Q · filed 2026-05-07 | $14.93M derived: sum of 2 quarters · filed 2026-05-07 | $24.39M derived: sum of 3 quarters · filed 2026-05-07 | $34.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $16.78M derived: sum of 2 quarters · filed 2026-03-10 | $26.67M derived: sum of 3 quarters · filed 2026-08-06 | $36.04M 10-K · filed 2026-03-10 |
| 2025-09-30 | $9.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.35M derived: sum of 2 quarters · filed 2026-08-06 | $28.73M 10-Q · filed 2025-11-06 | $38.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $19.26M 10-Q · filed 2026-08-06 | $28.89M derived: sum of 3 quarters · filed 2026-08-06 | $38.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.37M 10-Q · filed 2026-05-07 | $19.01M derived: sum of 2 quarters · filed 2026-05-07 | $28.44M derived: sum of 3 quarters · filed 2026-05-07 | $38.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $19.06M derived: sum of 2 quarters · filed 2026-03-10 | $29.60M derived: sum of 3 quarters · filed 2026-03-10 | $37.82M 10-K · filed 2026-03-10 |
| 2024-09-30 | $9.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.96M derived: sum of 2 quarters · filed 2025-11-06 | $28.19M 10-Q · filed 2025-11-06 | $35.71M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.76M 10-Q · filed 2025-08-07 | $26.28M derived: sum of 3 quarters · filed 2025-08-07 | $34.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $8.23M 10-Q · filed 2025-05-08 | $15.75M derived: sum of 2 quarters · filed 2025-05-08 | $23.49M derived: sum of 3 quarters · filed 2025-05-08 | $31.41M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $15.26M derived: sum of 2 quarters · filed 2025-02-27 | $23.18M derived: sum of 3 quarters · filed 2025-02-27 | $30.44M 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $15.66M derived: sum of 2 quarters · filed 2024-11-07 | $22.92M 10-Q · filed 2024-11-07 | $30.43M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $7.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $15.18M 10-Q · filed 2024-08-08 | $22.69M derived: sum of 3 quarters · filed 2024-08-08 | $27.96M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.26M 10-Q · filed 2024-05-15 | $14.77M derived: sum of 2 quarters · filed 2024-05-15 | $20.04M derived: sum of 3 quarters · filed 2024-05-15 | $28.65M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $12.78M derived: sum of 2 quarters · filed 2024-03-14 | $21.39M derived: sum of 3 quarters · filed 2024-03-14 | $27.96M 10-K · filed 2024-03-14 |
| 2022-09-30 | $5.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $13.88M derived: sum of 2 quarters · filed 2023-11-08 | $20.44M 10-Q · filed 2023-11-08 | $32.59M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $8.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $15.17M 10-Q · filed 2023-08-10 | $27.32M derived: sum of 3 quarters · filed 2023-08-10 | $31.88M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $6.57M 10-Q · filed 2023-05-11 | $18.71M derived: sum of 2 quarters · filed 2023-05-11 | $23.27M derived: sum of 3 quarters · filed 2023-05-11 | $27.43M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $16.70M derived: sum of 2 quarters · filed 2023-03-09 | $20.87M derived: sum of 3 quarters · filed 2023-03-09 | $24.38M 10-K · filed 2023-03-09 |
| 2021-09-30 | $4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $8.72M derived: sum of 2 quarters · filed 2022-11-14 | $12.23M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $7.67M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $3.51M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $14.91M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |